Rolf Kaiser

Research Topics

by # Publications/# Citations
  • Signs and Symptoms
  • Diseases

Register to see all

Co-author network

Co-author # Co-publications
Co-author # Co-publications

Register to see all


Top 5
# Referenced

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.

2014: M Büchert; A Frost; R Kaiser; M Medinger; K Mross; P Stopfer; M Studeny;

Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors.

2015: P Almi; P Blanc; C Caudai; E Cella; M Ciccozzi; A De Luca; S Di Giambenedetto; M Fabbiani; R Gagliardini; M Giovanetti; P Grima; R Kaiser; A Lo Presti; M Prosperi; B Rossetti; F Saladini; S Sierra; C Torti; I Vicenti; M Zazzi;

Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

2011: M Eichelbaum; HW Finnern; R Kaiser; M Shahidi; X Song; P Stopfer; H Varker; K Wilson;

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

2015: K Azuma; H Hayashi; F Hirai; R Kaiser; H Kaneda; K Konishi; T Kurata; M Miyazaki; K Nakagawa; I Okamoto; A Sarashina; T Seto; M Takeda; M Terashima; J Tsurutani; N Yagi;

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

2011: T Berg; P Braun; M Däumer; R Ehret; R Kaiser; H Knechten; G Naeth; M Stürmer; A Tappe; J Vachta; H Walter; F Wiesmann;

Register to see all


Humboldt Universität Berlin

Register to see all

No map available!

Title and Abstract from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Data mined from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Last MEDLINE®/PubMed® update: 1st of December 2015